Acute plateletpheresis and aprotinin reduces the need for blood transfusion following Ross operation.
The effect of acute intraoperative plateletpheresis (25% platelet yield) in combination with intraoperative low-dose aprotinin (2 million units) on blood conservation was investigated in 18 young adult patients undergoing elective Ross operation. The results were compared with a group of 19 similar patients without plateletpheresis (control group). The hematological and coagulation parameters at admission and discharge were statistically similar in both groups. The total blood product transfusion requirements were significantly reduced in the plateletpheresis group compared with the control group (3.2 units and 5.1 units, respectively, P=0.036). The total blood donor exposure was also reduced significantly in the plateletpheresis group compared with the control group (3.2 and 6.9 donors/patient, respectively, P<0.001). The direct costs for the hospital for the plateletpheresis procedure, including costs for all blood products, were similar to those for blood products alone in the control group. In summary, acute plateletpheresis in combination with low-dose aprotinin significantly reduces the blood product transfusions and blood donor exposures following the Ross operation; the treatment is cost-effective.
Al-Rashidi
Faleh
F
Cardiothoracic Surgery, University Hospital Lund, 221 85 Lund, Sweden.
Bhat
Misha
M
Pierre
Leif
L
Koul
Bansi
B
D000328:Adult; D001021:Aortic Valve / Q000601:surgery*; D007611:Aprotinin / Q000191:economics / Q000627:therapeutic use*; D016063:Blood Loss, Surgical / Q000517:prevention & control* / Q000706:statistics & numerical data; D001803:Blood Transfusion / Q000191:economics / Q000706:statistics & numerical data; D006348:Cardiac Surgical Procedures / Q000009:adverse effects* / Q000191:economics / Q000706:statistics & numerical data; D003131:Combined Modality Therapy; D003362:Cost-Benefit Analysis; D017558:Elective Surgical Procedures / Q000009:adverse effects; D005260:Female; D017048:Health Care Costs; D006490:Hemostatics / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007430:Intraoperative Care; D008297:Male; D008875:Middle Aged; D010983:Plateletpheresis / Q000191:economics / Q000706:statistics & numerical data; D012189:Retrospective Studies; D016896:Treatment Outcome
D006490:Hemostatics; D007611:Aprotinin